Abstract
We investigated the role of interleukin-10 (IL-10) in a neonatal mouse model of lethal group B streptococci (GBS) sepsis. Plasma IL-10 levels significantly increased at 24 and 48 h after GBS inoculation. Neutralization of IL-10 with specific antibodies had no effect on lethality. Administration of recombinant IL-10 at 20 or 4 h before challenge, but not at later times, resulted in decreased tumor necrosis factor alpha levels and improved survival. IL-10 could be potentially useful for the treatment of GBS sepsis.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Animals, Newborn
-
Interleukin-10 / antagonists & inhibitors
-
Interleukin-10 / blood
-
Interleukin-10 / pharmacology*
-
Mice
-
Mice, Inbred BALB C
-
Neutralization Tests
-
Recombinant Proteins / pharmacology
-
Streptococcal Infections / etiology
-
Streptococcal Infections / immunology
-
Streptococcal Infections / prevention & control*
-
Streptococcus agalactiae* / pathogenicity
-
Time Factors
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Recombinant Proteins
-
Tumor Necrosis Factor-alpha
-
Interleukin-10